IMPCL achieves highest ever turnover, crosses revenue Rs 160 crore in FY 2020-21

at 5:13 pm

New Delhi (NVI): Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of AYUSH has recorded a turnover of Rs 164.33 Crore (tentative figure) for the financial year 2020-21.

According to the statement, this is the highest number achieved in the company’s history and an all-time high profit of approximately Rs 12 crore is reported for the year.

“In the previous year 2019-20 best revenue figures of the company was Rs 97 Crore.  This growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of COVID-19 pandemic,” the government said.

Adding another feather in IMPCL’s cap, the Central Drugs Standards Control organisation (CDSCO) recently recommended its 18 Ayurvedic products for WHO-GMP/COPP certification subject to certain observations in March 2021.

During the COVID-19 pandemic, IMPCL was able to cater the needs of the country in the shortest time, probably the first company in the country to provide Immuno boosting medicines as AurakshaImmuno Boosting Kit.

“At Rs 350, it is one of the lowest-priced such kits and is also available on Amazon. Nearly 2 lakh such kits have been sold in the last two months,” the government said in a statement.

Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum. It has contributed towards research and development activities and 25 new proprietary Ayurvedic medicines as per the Essential Drug List (EDL).

Every Government institution doing business with IMPCL has praised the company for providing steady support to various health programmes and ensuring an unbroken supply of products during the e COVID-19 pandemic.